Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians
- Authors: Simanenkov V.I.1, Maev I.V.2, Tkacheva O.N.3, Alekseenko S.A.4, Andreev D.2, Bakulina N.V.1, Bakulin I.G.1, Bordin D.S.5,6,7, Vlasov T.D.8, Vorobyeva N.M.3, Grinevich V.B.9, Gubonina I.V.9, Drobizhev M.Y.10, Efremov N.S.3,11, Karateev A.E.12, Kotovskaya Y.V.3, Kravchuk I.9, Krivoborodov G.G.3,11, Kulchavenya E.V.13,14, Lila A.M.12,15, Maevskaya M.V.16, Nekrasova A.S.1, Poluektova E.A.16, Popkova T.V.12, Sablin O.A.17, Solovyeva O.I.1, Suvorov A.N.18, Tarasova G.N.19, Trukhan D.I.20, Fedotova A.V.11
-
Affiliations:
- Mechnikov North-Western State Medical University
- Yevdokimov Moscow State University of Medicine and Dentistry
- Russian Clinical and Research Center of Gerontology of Pirogov Russian National Research Medical University
- Far-East State Medical University
- Yevdokimov Moscow State University of Medicine and Dentistry, , Russia
- Loginov Moscow Clinical Scientific Center
- Tver State Medical University
- Pavlov First Saint Petersburg State Medical University
- Kirov Military Medical Academy
- Semashko National Research Institute of Public Health
- Pirogov Russian National Research Medical University
- Nasonova Research Institute of Rheumatology
- Novosibirsk Research Institute of Tuberculosis
- Novosibirsk State Medical University
- Russian Medical Academy of Continuous Professional Education
- Sechenov First Moscow State Medical University (Sechenov University)
- Nikiforov All-Russian Center for Emergency and Radiation Medicine
- Institute of Experimental Medicine
- Rostov State Medical University
- Omsk State Medical University
- Issue: Vol 94, No 8 (2022)
- Pages: 940-956
- Section: GUIDELINES
- URL: https://journals.rcsi.science/0040-3660/article/view/106723
- DOI: https://doi.org/10.26442/00403660.2022.08.201523
- ID: 106723
Cite item
Full Text
Abstract
This document was produced with the support of the National Medical Association for the Study of Comorbidities (NASС).
In 2021 the first multidisciplinary National Consensus on the pathophysiological and clinical aspects of Increased Epithelial Permeability Syndrome was published. The proposed guidelines are developed on the basis of this Consensus, by the same team of experts. Twenty-eight Practical Guidelines for Physicians statements were adopted by the Expert Council using the "delphic" method. Such main groups of epithelial protective drugs as proton pump inhibitors, bismuth drugs and probiotics are discussed in these Guidelines from the positions of evidence-based medicine. The clinical and pharmacological characteristics of such a universal epithelial protector as rebamipide, acting at the preepithelial, epithelial and subepithelial levels, throughout gastrointestinal tract, are presented in detail.
Full Text
##article.viewOnOriginalSite##About the authors
Vladimir I. Simanenkov
Mechnikov North-Western State Medical University
Author for correspondence.
Email: visimanenkov@mail.ru
ORCID iD: 0000-0002-1956-0070
д-р мед. наук, проф., проф. каф. внутренних болезней, клинической фармакологии и нефрологии ФГБОУ ВО «СЗГМУ им. И.И. Мечникова»
Russian Federation, Saint PetersburgIgor V. Maev
Yevdokimov Moscow State University of Medicine and Dentistry
Email: visimanenkov@mail.ru
ORCID iD: 0000-0001-6114-564X
акад. РАН, д-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней и гастроэнтерологии лечебного фак-та ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»
Russian Federation, MoscowOlga N. Tkacheva
Russian Clinical and Research Center of Gerontology of Pirogov Russian National Research Medical University
Email: visimanenkov@mail.ru
ORCID iD: 0000-0002-4193-688X
д-р мед. наук, проф., дир. ОСП РГНКЦ ФГАОУ ВО «РНИМУ им. Н.И. Пирогова»
Russian Federation, MoscowSergei A. Alekseenko
Far-East State Medical University
Email: visimanenkov@mail.ru
ORCID iD: 0000-0003-1724-9980
д-р мед. наук, проф., зав. каф. госпитальной терапии ФГБОУ ВО ДВГМУ
Russian Federation, KhabarovskDmitry Andreev
Yevdokimov Moscow State University of Medicine and Dentistry
Email: visimanenkov@mail.ru
ORCID iD: 0000-0002-4007-7112
канд. мед. наук, доц., доц. каф. пропедевтики внутренних болезней и гастроэнтерологии ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»
Russian Federation, MoscowNatalia V. Bakulina
Mechnikov North-Western State Medical University
Email: visimanenkov@mail.ru
ORCID iD: 0000-0003-4075-4096
д-р мед. наук, зав. каф. внутренних болезней, клинической фармакологии и нефрологии ФГБОУ ВО «СЗГМУ им. И.И. Мечникова»
Russian Federation, Saint PetersburgIgor G. Bakulin
Mechnikov North-Western State Medical University
Email: visimanenkov@mail.ru
ORCID iD: 0000-0002-6151-2021
д-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии ФГБОУ ВО «СЗГМУ им. И.И. Мечникова»
Russian Federation, Saint PetersburgDmitry S. Bordin
Yevdokimov Moscow State University of Medicine and Dentistry, , Russia; Loginov Moscow Clinical Scientific Center; Tver State Medical University
Email: visimanenkov@mail.ru
ORCID iD: 0000-0003-2815-3992
д-р мед. наук, проф., проф. каф. пропедевтики внутренних болезней и гастроэнтерологии ФГБОУ ВО «МГМСУ им. А.И. Евдокимова», зав. отд. патологии поджелудочной железы, желчных путей и верхних отделов пищеварительного тракта ГБУЗ «МКНЦ им. А.С. Логинова», проф. каф. поликлинической терапии и семейной медицины ФГБОУ ВО ТГМУ
Russian Federation, Moscow; Moscow; TverTimur D. Vlasov
Pavlov First Saint Petersburg State Medical University
Email: visimanenkov@mail.ru
ORCID iD: 0000-0002-6951-7599
д-р мед. наук, проф., зав. каф. патологической физиологии с курсом клинической патофизиологии ФГБОУ ВО «Первый СПб ГМУ им. акад. И.П. Павлова»
Russian Federation, Saint PetersburgNatalya M. Vorobyeva
Russian Clinical and Research Center of Gerontology of Pirogov Russian National Research Medical University
Email: visimanenkov@mail.ru
ORCID iD: 0000-0002-6021-7864
д-р мед. наук, зав. лаб. сердечно-сосудистого старения ОСП РГНКЦ ФГАОУ ВО «РНИМУ им. Н.И. Пирогова»
Russian Federation, MoscowVladimir B. Grinevich
Kirov Military Medical Academy
Email: visimanenkov@mail.ru
ORCID iD: 0000-0002-1095-8787
д-р мед. наук, проф., зав. 2-й каф. терапии (усовершенствования врачей) ФГБВОУ ВО «ВМА им. С.М. Кирова»
Russian Federation, Saint PetersburgIrina V. Gubonina
Kirov Military Medical Academy
Email: visimanenkov@mail.ru
ORCID iD: 0000-0002-6302-7767
канд. мед. наук, доц. 2 каф. терапии (усовершенствования врачей) ФГБВОУ ВО «ВМА им. С.М. Кирова»
Russian Federation, Saint PetersburgMichail Y. Drobizhev
Semashko National Research Institute of Public Health
Email: visimanenkov@mail.ru
ORCID iD: 0000-0002-1536-219X
д-р мед. наук, вед. науч. сотр. отд. изучения образа жизни и охраны здоровья населения ФГБНУ «Национальный НИИ общественного здоровья им. Н.А. Семашко»
Russian Federation, MoscowNikolay S. Efremov
Russian Clinical and Research Center of Gerontology of Pirogov Russian National Research Medical University; Pirogov Russian National Research Medical University
Email: visimanenkov@mail.ru
ORCID iD: 0000-0001-7785-3405
канд. мед. наук, доц., врач-уролог ОСП РГНКЦ ФГАОУ ВО «РНИМУ им. Н.И. Пирогова», доц. каф. урологии и андрологии ФГАОУ ВО «РНИМУ им. Н.И. Пирогова»
Russian Federation, Moscow; MoscowAndrey E. Karateev
Nasonova Research Institute of Rheumatology
Email: visimanenkov@mail.ru
ORCID iD: 0000-0002-1391-0711
д-р мед. наук, проф., зав. лаб. патофизиологии боли и клинического полиморфизма скелетно-мышечных заболеваний ФГБНУ «НИИ ревматологии им. В.А. Насоновой»
Russian Federation, MoscowYulia V. Kotovskaya
Russian Clinical and Research Center of Gerontology of Pirogov Russian National Research Medical University
Email: visimanenkov@mail.ru
ORCID iD: 0000-0002-1628-5093
Russian Federation, Moscow
Iurii Kravchuk
Kirov Military Medical Academy
Email: visimanenkov@mail.ru
ORCID iD: 0000-0001-8347-0531
д-р мед. наук, проф., проф. 2 каф. терапии (усовершенствования врачей) ФГБВОУ ВО «ВМА им. С.М. Кирова»
Russian Federation, Saint PetersburgGrigory G. Krivoborodov
Russian Clinical and Research Center of Gerontology of Pirogov Russian National Research Medical University; Pirogov Russian National Research Medical University
Email: visimanenkov@mail.ru
ORCID iD: 0000-0001-6433-4219
д-р мед. наук, зав. отд-нием урологии ОСП РГНКЦ ФГАОУ ВО «РНИМУ им. Н.И. Пирогова», проф. каф. урологии и андрологии ФГАОУ ВО «РНИМУ им. Н.И. Пирогова»
Russian Federation, Moscow; MoscowEkaterina V. Kulchavenya
Novosibirsk Research Institute of Tuberculosis; Novosibirsk State Medical University
Email: visimanenkov@mail.ru
ORCID iD: 0000-0001-8062-7775
д-р мед. наук, проф., гл. науч. сотр. ФГБУ «Новосибирский НИИ туберкулеза», рук. отд. урологии, проф. каф. туберкулеза ФГБОУ ВО НГМУ
Russian Federation, Novosibirsk; NovosibirskAleksander M. Lila
Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education
Email: visimanenkov@mail.ru
ORCID iD: 0000-0002-6068-3080
д-р мед. наук, проф., дир. ФГБНУ «НИИ ревматологии им. В.А. Насоновой», зав. каф. ревматологии ФГБОУ ДПО РМАНПО
Russian Federation, Moscow; MoscowMarina V. Maevskaya
Sechenov First Moscow State Medical University (Sechenov University)
Email: visimanenkov@mail.ru
ORCID iD: 0000-0001-8913-140X
д-р мед. наук, проф., консультант ЛДО №3 Университетской клинической больницы №2 ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)
Russian Federation, MoscowAnna S. Nekrasova
Mechnikov North-Western State Medical University
Email: visimanenkov@mail.ru
ORCID iD: 0000-0001-5198-9902
канд. мед. наук, доц. каф. внутренних болезней, клинической фармакологии и нефрологии ФГБОУ ВО «СЗГМУ им. И.И. Мечникова»
Russian Federation, Saint PetersburgElena A. Poluektova
Sechenov First Moscow State Medical University (Sechenov University)
Email: visimanenkov@mail.ru
ORCID iD: 0000-0003-1312-120X
д-р мед. наук, проф. каф. пропедевтики внутренних болезней гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифосовского ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)
Russian Federation, MoscowTatiana V. Popkova
Nasonova Research Institute of Rheumatology
Email: visimanenkov@mail.ru
ORCID iD: 0000-0001-5793-4689
д-р мед. наук, зав. лаб. системных ревматических заболеваний ФГБНУ «НИИ ревматологии им. В.А. Насоновой»
Russian Federation, MoscowOleg A. Sablin
Nikiforov All-Russian Center for Emergency and Radiation Medicine
Email: visimanenkov@mail.ru
ORCID iD: 0000-0002-2597-1220
д-р мед. наук, проф., зав. клин. отд. терапии и профпатологии Клиники №1, проф. каф. терапии Института дополнительного профессионального образования «Экстремальная медицина» ФГБУ «ВЦЭРМ им. А.М. Никифорова»
Russian Federation, Saint PetersburgOlga I. Solovyeva
Mechnikov North-Western State Medical University
Email: visimanenkov@mail.ru
ORCID iD: 0000-0003-0037-7855
канд. мед. наук, доц. каф. внутренних болезней, клинической фармакологии и нефрологии ФГБОУ ВО «СЗГМУ им. И.И. Мечникова»
Russian Federation, Saint PetersburgAlexander N. Suvorov
Institute of Experimental Medicine
Email: visimanenkov@mail.ru
ORCID iD: 0000-0003-2312-5589
чл.-кор. РАН, д-р мед. наук, проф., зав. каф. фундаментальных проблем медицины и медицинских технологий фак-та стоматологии и медицинских технологий СПбГУ, зав. отд. молекулярной микробиологии ФГБНУ ИЭИ
Russian Federation, Saint PetersburgGalina N. Tarasova
Rostov State Medical University
Email: visimanenkov@mail.ru
ORCID iD: 0000-0003-4054-9180
д-р мед. наук, проф., проф. каф. внутренних болезней ФГБОУ ВО РостГМУ
Russian Federation, Rostov on DonDmity I. Trukhan
Omsk State Medical University
Email: visimanenkov@mail.ru
ORCID iD: 0000-0002-1597-1876
д-р мед. наук, проф. каф. поликлинической терапии и внутренних болезней ФГБОУ ВО ОмГМУ
Russian Federation, OmskAnastasia V. Fedotova
Pirogov Russian National Research Medical University
Email: visimanenkov@mail.ru
ORCID iD: 0000-0002-2627-0485
канд. мед. наук, доц. каф. неврологии фак-та усовершенствования врачей ФГАОУ ВО «РНИМУ им. Н.И. Пирогова»
Russian Federation, MoscowReferences
- Симаненков В.И., Маев И.В., Ткачева О.Н., и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20(1):2758 [Simanenkov VI, Maev IV, Tkacheva ON, et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758 (in Russian)]. doi: 10.15829/1728-8800-2021-2758
- Robert A. Cytoprotection by prostaglandins. Gastroenterology. 1979;77(4 Pt. 1):761.
- Андреева Н.С., Реброва О.Ю., Зорин Н.А., и др. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. Медицинские технологии. Оценка и выбор. 2012;4(10):10-24 [Andreeva N, Rebrova O, Zorin H, et al. Systems for Assessing the Reliability of Scientific Evidence and the Grades of Recommendations: Comparison and Prospects for Unification. Meditsinskie tekhnologii. Otsenka i vybor. 2012;4(10):10-24 (in Russian)].
- Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37-43. doi: 10.1016/S0140-6736(12)60240-2
- Лазебник Л.Б., Конев Ю.В. Исторические особенности и семантические трудности использования терминов, обозначающих множественность заболеваний у одного больного. Экспериментальная и клиническая гастроэнтерология. 2018;(6):4-9 [Lazebnik LB, Konev YuV. Historical features and semantic difficulties of using the terms denoting multiplicity of diseases in one patient. Experimental and Clinical Gastroenterology. 2018;(6):4-9 (in Russian)].
- Оганов Р.Г., Симаненков В.И., Бакулин И.Г., и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019;18(1):5-66 [Oganov RG, Simanenkov VI, Bakulin IG, et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5-66 (in Russian)]. doi: 10.15829/1728-8800-2019-1-5-66
- Kadambi S, Abdallah M, Loh KP. Multimorbidity, Function, and Cognition in Aging. Clin Geriatr Med. 2020;36(4):569-84. doi: 10.1016/j.cger.2020.06.002
- Оганов Р.Г., Денисов И.Н., Симаненков В.И., и др. Коморбидная патология в клинической практике. Клинические рекомендации. Кардиоваскулярная терапия и профилактика. 2017;16(6):5-56 [Oganov RG, Denisov IN, Simanenkov VI, et al. Comorbidities in practice. Clinical guidelines. Cardiovascular Therapy and Prevention. 2017;16(6):5-56 (in Russian)]. doi: 10.15829/1728-8800-2017-6-5-56
- Лазебник Л.Б., Голованова Е.В., Волель Б.А., и др. Функциональные заболевания органов пищеварения. Синдромы перекреста. Клинические рекомендации Российского Научного Медицинского Общества Терапевтов и Научного Общества Гастроэнтерологов России. Экспериментальная и клиническая гастроэнтерология. 2021;(8):5-117 [Lazebnik LB, Golovanova EV, Volel BA, et al. Functional gastrointestinal disorders. Overlap syndrome Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine and Gastroenterological Scientific Society of Russia. Experimental and Clinical Gastroenterology. 2021;(8):5-117 (in Russian)]. doi: 10.31146/1682-8658-ecg-192-8-5-117
- Black CH, Drossman D, Talley N, et al. Functional gastrointestinal disorders: advances in understanding and management. Lancet. 2020;396(10263):1664-74. doi: 10.1016/S0140-6736(20)32115-2
- Richardson WS, Doster LM. Comorbidity and multimorbidity need to be placed in the context of a framework of risk, responsiveness, and vulnerability. J Clin Epidemiol. 2014;67(3):244-6. doi: 10.1016/j.jclinepi.2013.10.020
- Talley NJ. What Causes Functional Gastrointestinal Disorders? A Proposed Disease Model. Am J Gastroenterol. 2020;115(1):41-8. doi: 10.14309/ajg.0000000000000485
- Assimakopoulos SF, Triantos C, Maroulis I, Gogos C. The Role of the Gut Barrier Function in Health and Disease. Gastroenterology Res. 2018;11(4):261-3. doi: 10.14740/gr1053w
- Kierszenbaum AL, LL. Epithelium. Cell biology. In: Histology and Cell Biology: An Introduction to Pathology. Fifth Ed. Elsevier, 2020.
- Ramena Y, Ramena G. Cell-Cell Junctions and Epithelial Differentiation. 2018;2:111.
- Shashikanth N, Yeruva S, Ong MLDM, et al. Epithelial Organization: The Gut and Beyond. Compr Physiol. 2017;7(4):1497-518. doi: 10.1002/cphy.c170003
- Dejana E, Bazzoni G, Lampugnani MG. Vascular Endothelial (VE)-Cadherin: Only an Intercellular Glue? Exp Cell Res. 1999;252(1):13-9. doi: 10.1006/excr.1999.4601
- Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev. 2004;84(3):869-901. doi: 10.1152/physrev.00035.2003
- Duong CN, Vestweber D. Mechanisms Ensuring Endothelial Junction Integrity Beyond VE-Cadherin. Front Physiol. 2020;11:519. doi: 10.3389/fphys.2020.00519
- Greene C, Hanley N, Campbell M. Claudin-5: gatekeeper of neurological function. Fluids Barriers CNS. 2019;16(1):3. doi: 10.1186/s12987-019-0123-z
- Komarova YA, Kruse K, Mehta D, Malik AB. Protein Interactions at Endothelial Junctions and Signaling Mechanisms Regulating Endothelial Permeability. Circ Res. 2017;120(1):179-206. doi: 10.1161/CIRCRESAHA.116.306534
- Farré R, Vicario M. Abnormal Barrier Function in Gastrointestinal Disorders. Handb Exp Pharmacol. 2017;239:193-217. doi: 10.1007/164_2016_107
- Al-Sadi R, Guo S, Ye D, et al. TNF-α Modulation of Intestinal Tight Junction Permeability Is Mediated by NIK/IKK-α Axis Activation of the Canonical NF-kВ Pathway. Am J Pathol. 2016;186(5):1151-65. doi: 10.1016/j.ajpath.2015.12.016
- Cunningham KE, Turner JR. Myosin light chain kinase: pulling the strings of epithelial tight junction function. Ann N Y Acad Sci. 2012;1258(1):34-42. doi: 10.1111/j.1749-6632.2012.06526.x
- Jacob C, Yang PC, Darmoul D, et al. Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and beta-arrestins. J Biol Chem. 2005;280(36):31936-48. doi: 10.1074/jbc.M506338200
- Gangwar R, Meena AS, Shukla PK, et al. Calcium-mediated oxidative stress: a common mechanism in tight junction disruption by different types of cellular stress. Biochem J. 2017;474(5):731-49. doi: 10.1042/BCJ20160679
- Ohlsson L, Gustafsson A, Lavant E, et al. Leaky gut biomarkers in depression and suicidal behavior. Acta Psychiatr Scand. 2019;139(2):185-93. doi: 10.1111/acps.12978
- Sochocka M, Donskow-Łysoniewska K, Diniz BS, et al. The Gut Microbiome Alterations and Inflammation-Driven Pathogenesis of Alzheimer's Disease – a Critical Review. Mol Neurobiol. 2019;56(3):1841-51. doi: 10.1007/s12035-018-1188-4
- Schwiertz A, Spiegel J, Dillmann U, et al. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson's disease. Parkinsonism Relat Disord. 2018;50:104-7. doi: 10.1016/j.parkreldis.2018.02.022
- Nikiforova AS. Stress-induced gastrointestinal motility is responsible for epileptic susceptibility. Med Hypotheses. 2014;82(4):442-51. doi: 10.1016/j.mehy.2014.01.020
- Crapser J, Ritzel R, Verma R, et al. Ischemic stroke induces gut permeability and enhances bacterial translocation leading to sepsis in aged mice. Aging (Albany NY). 2016;8(5):1049-63. doi: 10.18632/aging.100952
- Fyderek K, Strus M, Kowalska-Duplaga K, et al. Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease. World J Gastroenterol. 2009;15(42):5287-94. doi: 10.3748/wjg.15.5287
- Garcia-Hernandez V, Quiros M, Nusrat A. Intestinal epithelial claudins: expression and regulation in homeostasis and inflammation. Ann N Y Acad Sci. 2017;1397(1):66-79. doi: 10.1111/nyas.13360
- Zeissig S, Bürgel N, Günzel D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut. 2007;56(1):61-72. doi: 10.1136/gut.2006.094375
- Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49(6):1877-87. doi: 10.1002/hep.22848
- Sinagra E, Pompei G, Tomasello G, et al. Inflammation in irritable bowel syndrome: Myth or new treatment target? World J Gastroenterol. 2016;22(7):2242-55. doi: 10.3748/wjg.v22.i7.224
- Ulluwishewa D, Anderson R, McNabb W. Regulashion of tight junction permeability by intestinal bacteria and Dietary components. J Nutr. 2011;141(5):769-76. doi: 10.3945/jn.110.135657
- Zhao Y, Chen F, Wu W, et al. GPR43 mediates microbiota metabolite SCFA regulation of antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR and STAT3. Mucosal Immunol. 2018;11(3):752-62. doi: 10.1038/mi.2017.118
- Johansson ME, Hansson GC. Immunological aspects of intestinal mucus and mucins. Nat Rev Immunol. 2016;16(10):639-49. doi: 10.1038/nri.2016.88
- Chakaroun RM, Massier L, Kovacs P. Gut Microbiome, Intestinal Permeability, and Tissue Bacteria in Metabolic Disease: Perpetrators or Bystanders? Nutrients. 2020;12(4):1082. doi: 10.3390/nu12041082
- Schoultz I, Keita ÅV. The Intestinal Barrier and Current Techniques for the Assessment of Gut Permeability. Cells. 2020;9(8):1909. doi: 10.3390/cells9081909
- De Munck TJI, Xu P, Verwijs HJA, et al. Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta- analysis. Liver Int. 2020;40(12):2906-16. doi: 10.1111/liv.14696
- Якупова А.А., Абдулхаков С.Р., Залялов Р.К., и др. Методы оценки кишечной проницаемости: обзор литературы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(1):20-30 [Iakupova AA, Abdulkhakov SR, Zalyalov RK, et al. Intestinal Permeability Assays: a Review. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(1):20-30 (in Russian)]. doi: 10.22416/1382-4376-2021-31-1-20-30
- Xu S, Ilyas I, Little PJ, et al. Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacol Rev. 2021;73(3):924-67. doi: 10.1124/pharmrev.120.000096
- Ивашкин В.Т., Маев И.В., Лапина Т.Л., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(1):55-70 [Ivashkin VT, Mayev IV, Lapina TL, et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(1):55-70 (in Russian)]. doi: 10.22416/1382-4376-2018-28-1-55-70
- Prados-Torres A, Cura-González ID, Prados-Torres JD, et al. MULTIPAP Study: Improving healthcare for patients with multimorbidity. Br J Gen Pract. 2020;70(Suppl. 1):bjgp20X711257. doi: 10.3399/bjgp20X711257
- Ивашкин В.Т., Маев И.В., Трухманов А.С., и др. Депрескрайбинг ингибиторов протонной помпы и выбор оптимального препарата данной группы (по результатам научного форума, состоявшегося в рамках XXVI Объединенной Российской гастроэнтерологической недели). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(6):7-18 [Ivashkin VT, Maev IV, Trukhmanov AS, et al. Deprescribing and Optimal Selection of Proton Pump Inhibitors (Contributions of the 26th United Russian Gastroenterology Week). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(6):7-18 (in Russian)]. doi: 10.22416/1382-4376-2020-30-6-7-18
- Симаненков В.И., Сундукова З.Р., Соловьева О.И. Возможности мультитаргетной терапии больных с синдромом раздраженного кишечника. Consilium Medicum. 2017;19(8-2):37-44 [Simanenkov VI, Sundukova ZR, Solovyeva OI. Complex therapy of irritable bowel syndrome. Consilium Medicum. 2017;19(8-2):37-44 (in Russian)]. doi: 10.26442/2075-1753_19.8.2.37-44
- Yoshimura K, Delbarre SG, Kraus E, Boland CR. The effects of omeprazole and famotidine on mucin and PGE2 release in the rat stomach. Aliment Pharmacol Ther. 1996;10(1):111-7. doi: 10.1111/j.1365-2036.1996.tb00184.x
- Skoczylas T, Sarosiek I, Sostarich S, et al. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. Dig Dis Sci. 2003;48(2):322-8. doi: 10.1023/a:1021983611768
- Jaworski T, Sarosiek I, Sostarich S, et al. Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance. Dig Dis Sci. 2005;50(2):357-65. doi: 10.1007/s10620-005-1611-3
- Wauters L, Ceulemans M, Frings D, et al. Proton Pump Inhibitors Reduce Duodenal Eosinophilia, Mast Cells, and Permeability in Patients With Functional Dyspepsia. Gastroenterology. 2021;160(5):1521-31.e9. doi: 10.1053/j.gastro.2020.12.016
- Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018;3(4):231-41. doi: 10.1016/S2468-1253(18)30037-2
- Kim JH, Park SH, Cho CS, et al. Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity. Gut Liver. 2014;8(4):371-9. doi: 10.5009/gnl.2014.8.4.371
- Zhang S, Qing Q, Bai Y, et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. 2013;58(7):1991-2000. doi: 10.1007/s10620-013-2606-0
- Pittayanon R, Piyachaturawat P, Rerknimitr R, et al. Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial. J Gastroenterol Hepatol. 2019;34(9):1517-22. doi: 10.1111/jgh.14671
- Zhang WT, Wang MR, Hua GD, et al. Inhibition of Aspirin-Induced Gastrointestinal Injury: Systematic Review and Network Meta-Analysis. Front Pharmacol. 2021;12:730681. doi: 10.3389/fphar.2021.730681
- Macke L, Schulz C, Koletzko L, Malfertheiner P. Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies. Aliment Pharmacol Ther. 2020;51(5):505-26. doi: 10.1111/apt.15604
- Washio E, Esaki M, Maehata Y, et al. Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-Inflammatory Drug-Induced Small Bowel Injury: A Randomized, Placebo-Controlled Trial. Clin Gastroenterol Hepatol. 2016;14(6):809-15.e1. doi: 10.1016/j.cgh.2015.10.022
- Kurokawa S, Katsuki S, Fujita T, et al. A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol. 2014;49(2):239-44. doi: 10.1007/s00535-013-0805-261
- Kim TJ, Kim ER, Hong SN, et al. Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users. Sci Rep. 2019;9(1):11696. doi: 10.1038/s41598-019-48173-6
- Xu N, Zhang C, Jing L, et al. Protective effect and mechanism of rebamipide on NSAIDs associated small bowel injury. Int Immunopharmacol. 2021;90:107136. doi: 10.1016/j.intimp.2020.107136
- Tanigawa T, Watanabe T, Higashimori A, et al. Rebamipide ameliorates indomethacin-induced small intestinal damage and proton pump inhibitor-induced exacerbation of this damage by modulation of small intestinal microbiota. PLoS One. 2021;16(1):e0245995. doi: 10.1371/journal.pone.0245995
- Tsang CN, Ho KS, Sun H, Chan WT. Tracking Bismuth anti-ulcer drug uptake in single Helicobacter pylori cells. J Am Chem Soc. 2011;133(19):7355-7. doi: 10.1021/ja2013278
- Konturek SJ, Radecki T, Piastucki I, et al. Gastrocytoprotection by colloidal bismuth subcitrate (De-Nol) and sucralfate. Role of endogenous prostaglandins. Gut. 1987;28(2):201-5. doi: 10.1136/gut.28.2.201
- Пахомова И.Г. Новые возможности в минимизации риска НПВП-индуцированных гастропатий. РМЖ. 2014;10:772 [Pahomova IG. Novye vozmozhnosti v minimizatsii riska NPVP-indutsirovannykh gastropatii. RMZh. 2014;10:772 (in Russian)].
- Ford AC, Malfertheiner P, Giguere M, et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol. 2008;14(48):7361-70. doi: 10.3748/wjg.14.7361
- Bismuth Salts for Gastrointestinal Issues: A Review of the Clinical Effectiveness and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2015.
- Yan F, Polk DB. Probiotics and Probiotic-Derived Functional Factors – Mechanistic Insights Into Applications for Intestinal Homeostasis. Front Immunol. 2020;11:1428. doi: 10.3389/fimmu.2020.01428
- Ramezani Ahmadi A, Sadeghian M, Alipour M, et al. The Effects of Probiotic/Synbiotic on Serum Level of Zonulin as a Biomarker of Intestinal Permeability: A Systematic Review and Meta-Analysis. Iran J Public Health. 2020;49(7):1222-31. doi: 10.18502/ijph.v49i7.3575
- La Fata G, Weber P, Mohajeri MH. Probiotics and the Gut Immune System: Indirect Regulation. Probiotics Antimicrob Proteins. 2018;10(1):11-21. doi: 10.1007/s12602-017-9322-6
- Shimura M, Mizuma M, Nakagawa K, et al. Probiotic-related bacteremia after major hepatectomy for biliary cancer: a report of two cases. Surg Case Rep. 2021;7(1):133. doi: 10.1186/s40792-021-01216-5.75
- Zhu L, Han J, Li L, et al. Claudin Family Participates in the Pathogenesis of Inflammatory Bowel Diseases and Colitis-Associated Colorectal Cancer. Front Immunol. 2019;10:1441. doi: 10.3389/fimmu.2019.01441
- Lin S, Shen Y. The efficacy and safety of probiotics for prevention of chemoradiotherapy-induced diarrhea in people with abdominal and pelvic cancer: a systematic review and meta-analysis based on 23 randomized studies. Int J Surg. 2020;84:69-77. doi: 10.1016/j.ijsu.2020.10.012
- Liao W, Chen C, Wen T, Zhao Q. Probiotics for the Prevention of Antibiotic-associated Diarrhea in Adults: A Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Gastroenterol. 2021;55(6):469-80. doi: 10.1097/MCG.0000000000001464
- Wang S, Xu M, Wang W, et al. Systematic Review: Adverse Events of Fecal Microbiota Transplantation. PLoS One. 2016;11(8):e0161174. doi: 10.1371/journal.pone.0161174
- Fecal Microbiota for Transplantation: Safety Alert – Risk of Serious Adverse Events Likely Due to Transmission of Pathogenic Organisms, Posted 03.12.2020. Available at: https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota transplantation-safety-alert-risk-serious-adverse-events-likely-due-transmission. Accessed: 08.03.2022.
- Blesl A, Stadlbauer V. The Gut-Liver Axis in Cholestatic Liver Diseases. Nutrients. 2021;13(3):1018. doi: 10.3390/nu13031018
- Lajczak-McGinley NK, Porru E, Fallon CM, et al. The secondary bile acids, ursodeoxycholic acid and lithocholic acid, protect against intestinal inflammation by inhibition of epithelial apoptosis. Physiol Rep. 2020;8(12):e14456. doi: 10.14814/phy2.14456
- Wang Z, Chen J, Chen Z, et al. Clinical effects of ursodeoxycholic acid on patients with ulcerative colitis may improve via the regulation of IL-23-IL-17 axis and the changes of the proportion of intestinal microflora. Saudi J Gastroenterol. 2021;27(3):149-57. doi: 10.4103/sjg.SJG_462_20
- Лищук Н.Б., Симаненков В.И., Тихонов С.В. Дифференцированная терапия «некислых» форм гастроэзофагеальной рефлюксной болезни. Терапевтический архив. 2017;89(4):57-63 [Lishchuk NB, Simanenkov VI, Tikhonov SV. Differentiation therapy for non-acidic gastroesophageal reflux disease. Terapevticheskii arkhiv (Ter. Arkh.). 2017;89(4):57-63 (in Russian)]. doi: 10.17116/terarkh201789457-63
- Peng S, Huo X, Rezaei D, et al. In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids. Am J Physiol Gastrointest Liver Physiol. 2014;307(2):G129-39. doi: 10.1152/ajpgi.00085.2014
- Kim BT, Kim KM, Kim KN. The Effect of Ursodeoxycholic Acid on Small Intestinal Bacterial Overgrowth in Patients with Functional Dyspepsia: A Pilot Randomized Controlled Trial. Nutrients. 2020;12(5):1410. doi: 10.3390/nu12051410
- Keely SJ, Steer CJ, Lajczak-McGinley NK. Ursodeoxycholic acid: a promising therapeutic target for inflammatory bowel diseases? Am J Physiol Gastrointest Liver Physiol. 2019;317(6):G872-81. doi: 10.1152/ajpgi.00163.2019
- Golden JM, Escobar OH, Nguyen MVL, et al. Ursodeoxycholic acid protects against intestinal barrier breakdown by promoting enterocyte migration via EGFR- and COX-2-dependent mechanisms. Am J Physiol Gastrointest Liver Physiol. 2018;315(2):G259-71. doi: 10.1152/ajpgi.00354.2017
- Звяглова М.Ю., Князев О.В., Парфенов А.И. Фармакологический и клинический профиль ребамипида: новые терапевтические мишени. Терапевтический архив. 2020;92(2):104-11 [Zvyaglova MYu, Knyazev OV, Parfenov AI. Pharmacological and clinical feature of rebamipide: new therapeutic targets. Therapeutic Archive (Ter. Arkh.). 2020;92(2):104-11 (in Russian)]. doi: 10.26442/00403660.2020.02.000569
- Markovic M, Zur M, Dahan A, Cvijić S. Biopharmaceutical characterization of rebamipide: The role of mucus binding in regional-dependent intestinal permeability. Eur J Pharm Sci. 2020;152:105440. doi: 10.1016/j.ejps.2020.105440
- Kim CE, Kim YJ, Hwang MW, et al. Cevimeline-induced anti-inflammatory effect through upregulations of mucins in the ocular surface of a dry eye mouse model. Biomed Pharmacother. 2021;139:111571. doi: 10.1016/j.biopha.2021.111571
- Tanigawa T, Watanabe T, Higashimori A, et al. Rebamipide ameliorates indomethacin-induced small intestinal damage and proton pump inhibitor-induced exacerbation of this damage by modulation of small intestinal microbiota. PLoS One. 2021;16(1):e0245995. doi: 10.1371/journal.pone.0245995
- Lee JS, Jeon SW, Lee HS, et al. Rebamipide for the improvement of Gastric Atrophy and Intestinal Metaplasia: A Prospective, Randomized, Pilot Study. Dig Dis Sci. 2021. doi: 10.1007/s10620-021-07038-7
- Cryer B. Mucosal defense and repair. Role of prostaglandins in the stomach and duodenum. Gastroenterol Clin North Am. 2001;30(4):877-vi. doi: 10.1016/s0889-8553(05)70218-1
- Suetsugu H, Ishihara S, Moriyama N, et al. Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa. J Lab Clin Med. 2000;136(1):50-7. doi: 10.1067/mlc.2000.107303
- Tanigawa T, Watanabe T, Ohkawa F, et al. Rebamipide, a mucoprotective drug, inhibits NSAIDs-induced gastric mucosal injury: possible involvement of the downregulation of 15-hydroxyprostaglandin dehydrogenase. J Clin Biochem Nutr. 2011;48(2):149-53. doi: 10.3164/jcbn.10-75
- Gweon TG, Park JH, Kim BW, et al. Incheon and Western Kyonggi Gastrointestinal Study. Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro-Esophageal Reflux Disease. Gut Liver. 2018;12(1):46-50. doi: 10.5009/gnl17078
- Jaafar MH, Safi SZ, Tan MP, et al. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2018;63(5):1250-60. doi: 10.1007/s10620-017-4871-9
- Del Valle-Pinero AY, Van Deventer HE, Fourie NH, et al. Gastrointestinal permeability in patients with irritable bowel syndrome assessed using a four probe permeability solution. Clin Chim Acta. 2013;418:97-101. doi: 10.1016/j.cca.2012.12.032
- Симаненков В.И., Бакулина Н.В., Некрасова А.С., и др. Динамика клинических проявлений синдрома раздраженного кишечника на фоне применения цитопротектора ребамипида. Промежуточные результаты программы СОКРАТ. Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2021;13(3):75-82 [Simanenkov VI, Bakulina NV, Nekrasova AS, et al. Dynamics of clinical manifestations of irritable bowel syndrome against the back-ground of cytoprotector rebamipide intake: intermediate results of the SOKRAT program. Herald of North-Western State Medical University named after I.I. Mechnikov. 2021;13(3):75-82 (in Russian)]. doi: 10.17816/mechnikov88094
- Ивашкин В.Т., Трухманов А.С., Гоник М.И. Применение ребамипида в лечении гастроэзофагеальной рефлюксной болезни. Терапевтический архив. 2020;92(4):98-104 [Ivashkin VT, Trukhmanov AS, Gonik MI. Rebamipide using in gastroesophageal reflux disease treatment. Terapevticheskii arkhiv (Ter. Arkh.). 2020;92(4):98-104 (in Russian)]. doi: 10.26442/00403660.2020.04.000568
- Kim GH, Lee HL, Joo MK, et al. Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double-Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study. Gut Liver. 2021;15(6):841-50. doi: 10.5009/gnl20338
- Liu J, Xiong Z, Geng X, Cui M. Rebamipide with Proton Pump Inhibitors (PPIs) versus PPIs Alone for the Treatment of Endoscopic Submucosal Dissection-Induced Ulcers: A Meta-analysis. Biomed Res Int. 2020;2020:7196782. doi: 10.1155/2020/7196782
- Ивашкин В.Т., Маев И.В., Царьков П.В., и др. Диагностика и лечение язвенной болезни у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(1):49-70 [Ivashkin VT, Maev IV, Tsarkov P, et al. Diagnosis and Treatment of Peptic Ulcer in Adults (Clinical Guidelines of the Russian Gastroenterological Association, Russian Society of Colorectal Surgeons and the Russian Endoscopic Society). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(1):49-70 (in Russian)]. doi: 10.22416/1382-4376-2020-30-1-49-70
- Zhang S, Qing Q, Bai Y, et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. 2013;58(7):1991-2000. doi: 10.1007/s10620-013-2606-0
- Makiyama K, Takeshima F, Hamamoto T. Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis: a prospective study report. Dig Dis Sci. 2005;50(12):2323-9. doi: 10.1007/s10620-005-3055-1
- Honcharuk LM, Fediv OI, Hresko SO, et al. Analysis of long-term results of pathogenetic treatment of Helicobacter pylori-associated gastroduodenopathies induced by nonsteroidal anti-inflammatory drugs in patients with osteoarthritis. J Med Life. 2021;14(2):176-80. doi: 10.25122/jml-2020-0176
- Andreev DN, Maev IV, Dicheva DT. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies. J Clin Med. 2019;8(9):1498. doi: 10.3390/jcm8091498
- Kamada T, Sato M, Tokutomi T, et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res Int. 2015;2015:865146. doi: 10.1155/2015/865146
- Lawrance IC. Novel topical therapies for distal colitis. World J Gastrointest Pharmacol Ther. 2010;1(5):87-93. doi: 10.4292/wjgpt.v1.i5.87
- Min DS. A Potential Efficacy of Rebamipide as Anti-gastric Cancer Drug. J Life Sci. 2016;26(10):1214-7. doi: 10.5352/JLS.2016.26.10.1214
- Tanigawa T, Pai R, Arakawa T, Tarnawski A.S. Rebamipide Inhibits Gastric Cancer Cell Growth. Dig Dis Sci. 2007;52(1):240-7. doi: 10.1007/s10620-006-9226-x
- Seo GH, Lee H. Chemopreventive Effect of Rebamipide against Gastric Cancer in Patients who undergo Endoscopic Resection for Early Gastric Neoplasms: A Nationwide Claims Study. Digestion. 2019;100(4):221-8. doi: 10.1159/000495288
- Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(04):365-88. doi: 10.1055/a-0859-1883
- Гриневич В.Б., Губонина И.В., Дощицин В.Л., и др. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020. Кардиоваскулярная терапия и профилактика. 2020;19(4):2630 [Grinevich VB, Gubonina IV, Doshchitsin VL, et al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention. 2020;19(4):2630 (in Russian)]. doi: 10.15829/1728-8800-2020-2630
- Ткачева О.Н., Котовская Ю.В., Алексанян Л.А., и др. Новая коронавирусная инфекция SARS-CoV-2 у пациентов пожилого и старческого возраста: особенности профилактики, диагностики и лечения. Согласованная позиция экспертов Российской ассоциации геронтологов и гериатров. Кардиоваскулярная терапия и профилактика. 2020;19(3):2601 [Tkacheva ON, Kotovskaya YuV, Aleksanyan LA, et al. Novel coronavirus infection SARS-CoV-2 in elderly and senile patients: prevention, diagnosis and treatment. Expert Position Paper of the Russian Association of Gerontology and Geriatrics. Cardiovascular Therapy and Prevention. 2020;19(3):2601 (in Russian)]. doi: 10.15829/1728-8800-2020-2601
- Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261-70. doi: 10.1586/egh.10.25
- Toshikazu Y. Rebamipide: a gastrointestinal protective drug with pleiotropic activities Expert Rev. Gastroenterol Hepatol. 2010;4(3):261-70. DOI:10.1586 / egh.10.25
- Seo GH, Lee H. Chemopreventive Effect of Rebamipide against Gastric Cancer in Patients who undergo Endoscopic Resection for Early Gastric Neoplasms: A Nationwide Claims Study. Digestion. 2019;100(4):221-8. doi: 10.1159/000495288
![](/img/style/loading.gif)